PTC Therapeutics (PTCT) PT Raised to $70 at Citi, 'Post-data, we increased our sepiapterin POS to 90%'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
PTC Therapeutics (PTCT) PT Raised to $37 at Goldman Sachs, 'stock in an increasingly precarious position ahead of higher risk'
May 17, 2023 2:39 PM EDT(Updated - May 17, 2023 2:40 PM EDT)
Goldman Sachs analyst Paul Choi raised the price target on PTC Therapeutics (NASDAQ: PTCT) to $37.00 (from $35.00) while maintaining a Sell rating.
The analyst comments "
Sepiapterin shows consistent efficacy and clean safety; MOVE-FA data later in May the next key catalyst. PTCT shares are trading up to a 52-week high (+42% YTD... More
PTC Therapeutics (PTCT) Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients
May 17, 2023 7:02 AM EDTPTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the primary endpoint was achieved in the APHENITY, Phase 3 registration-directed clinical trial of sepiapterin in adult and pediatric patients with phenylketonuria (PKU).
"The positive results from the APHENITY trial bring us one step... More
